Strengthen the case for your drug program.
We find the questions public data can answer for your compound, and answer them with established methods. You get evidence ready for grant reviewers, investors, partners and regulators.
We find the questions. You get the evidence.
We start from your program and its next milestone, search the public omics and biomedical data, and keep only the questions the data can really answer. Every analysis uses established methods, and the report documents how each result was obtained.
Share your program
Your compound and its next milestone.
an email or a callWe find the questions
Each one checked against public data before we promise it.
a short plan · fixed priceWe run the analysis
Established methods, chosen for each question.
you see the draft firstYou get the evidence
Figures, full results and methods text for your grants and decks.
report · spreadsheetsQuestions that strengthen a drug program.
From bulk and single-cell RNA to proteomics, spatial and genetic data.
Where is your target?
Which cell types and tissue areas make it: in diseased tissue for efficacy, across the healthy body for safety.
What changes in disease?
Which genes, transcription factors and pathways change across disease stages and patient groups, in the cells that matter for your drug.
Is there genetic support?
Human genetic evidence linking your target to the disease.
Has your mechanism been tested?
Public experiments that block or activate your target or its pathway, and what they changed.
Which patients?
Who shows the biology your drug acts on, and which markers could find them.
Do your models match patients?
How your mouse and cell models compare with the human disease.
AI models trained on 50M+ single cells.
Our models place every single-cell dataset we analyze in the context of its tissue of origin, so no result is read in a vacuum.
Prefer to run analyses yourself? Our platform automates single-cell workflows, from your data to a full report and results.
Request platform access →Evidence you can use, and defend.
You own the results
Use them in grant applications, regulatory filings and investor decks. We claim no rights in them.
Licence-checked data
Every public dataset is checked for a licence that allows commercial use, before it goes into your report.
Established methods
Every analysis uses established statistical and machine learning methods, and the report documents how each result was obtained.
For drug development
From target discovery to IND-enabling studies. Not for diagnosis or treatment decisions.
What does VarnaOps do?
It helps biotech teams strengthen the case for their compound with grant reviewers, investors, partners and regulators. We analyze publicly available omics and biomedical data, or a team's own data, with established statistical and machine learning methods, to answer the questions behind a drug program: which cells a drug acts on and which it leaves alone, how those cells change in disease, and what that means for the program.
How does a project work?
You tell us about your program and its next milestone, by email or on a call. We send a short plan of the questions the data can answer, with a fixed price, half at the start and half on delivery, agreed before any work begins. You see the draft and can comment before the final report, which comes with its figures, the full results as spreadsheets, and methods text you can reuse in grant applications and investor slides.
How long does it take?
Most projects deliver a complete draft within 8 weeks of the first payment; the plan states the date.
What if a question can't be answered?
We replace it with one of similar size, or take its share off the final payment.
Who owns the results, and can we publish them?
You do, and yes. You keep ownership of the data you share with us and of every result we produce from it; we claim no rights in either. Use the results in papers, grant applications and internal work alike. If you publish, cite the original studies behind the data: every report lists them, with their licences. Acknowledging VarnaOps is welcome but not required.